{
    "2021-12-20": [
        [
            {
                "time": "",
                "original_text": "药明康德、康龙化成均跌超8%，CRO板块持续低迷",
                "features": {
                    "keywords": [
                        "药明康德",
                        "康龙化成",
                        "CRO",
                        "板块",
                        "低迷"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【异动股】康龙化成(03759.HK)跌7.79%",
                "features": {
                    "keywords": [
                        "康龙化成",
                        "异动股",
                        "下跌"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "CRO板块连续下滑，药明康德一度跌近9%",
                "features": {
                    "keywords": [
                        "CRO",
                        "板块",
                        "下滑",
                        "药明康德"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "CRO概念持续走弱，药明康德领跌",
                "features": {
                    "keywords": [
                        "CRO",
                        "概念",
                        "走弱",
                        "药明康德",
                        "领跌"
                    ],
                    "sentiment_score": -0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "CRO"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "百诚医药今日创业板上市，如何在CRO浪潮中乘风破浪",
                "features": {
                    "keywords": [
                        "百诚医药",
                        "创业板",
                        "上市",
                        "CRO",
                        "浪潮"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "CRO"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "CXO增长可持续性强，看好中药板块投资机会",
                "features": {
                    "keywords": [
                        "CXO",
                        "增长",
                        "可持续性",
                        "中药",
                        "投资机会"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "CXO",
                        "中药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "北上资金加速流入A股，投资风格转向周期股",
                "features": {
                    "keywords": [
                        "北上资金",
                        "A股",
                        "投资风格",
                        "周期股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "周期股"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}